The makers of Taxotere face a woman’s recent chemotherapy hair loss lawsuit over allegations that she suffered suffered permanent and irreversible hair loss as a result of taking Taxotere, a breast cancer treatment medication.

Plaintiff Jennifer N. filed the chemotherapy hair loss lawsuit in Louisiana federal court joining growing multidistrict litigation (MDL) against the company. The lawsuit was filed on July 2, 2018.

According to the chemotherapy hair loss lawsuit, Jennifer is a resident of the state of Florida. She says that she took Taxotere between Jan. 29, 2014 and April 2, 2014. However, she says that she suffered “permanent/persistent hair loss and diffuse thinning of hair” as a result of her use of Taxotere.

The chemotherapy hair loss lawsuit was filed on multiple counts including failure to warn, negligence, negligent misrepresentation, fraudulent misrepresentation, fraudulent concealment, and fraud and deceit.

Jennifer demands a trial by jury.

Overview: Chemotherapy Hair Loss Lawsuit

Thousands of lawsuits have been filed against the makers of Taxotere, Sanofi Aventis, in continually growing multidistrict litigation (MDL) filed against the company. The lawsuits allege that women are suffering from permanent hair loss side effects due to the company’s failure to disclose warnings that permanent hair loss may occur.

Sanofi Avantis is being accused of selling a defective, unsafe, and dangerous medication. Other accusations against them include negligently designing and manufacturing Taxotere.

In fact, while warning labels cautioned women of permanent hair loss side effects associated with Taxotere in Europe and Canada, plaintiffs say no such warnings were available to consumers in the United States until 2015 — nearly 20 years after Taxotere’s approval by the FDA.

The U.S. Food and Drug Administration (FDA) first approved Taxotere in May 2004. Although common for women to understand that undergoing chemotherapy may result in hair loss because it is a normal and expected side effect. The plaintiffs allege they were completely unaware how they could suffer permanent hair loss side effects and that hair growth would never return after undergoing the treatment.

Patients filing a chemotherapy hair loss lawsuit include those who were administered Taxotere as part of a chemotherapy treatment plan, then later developed permanent hair loss, or permanent alopecia because of the Taxotere.

If you or someone you know have suffered from permanent hair loss side effects after taking Taxotere, you may be eligible to file a chemotherapy hair loss lawsuit. In fact, filing a chemotherapy hair loss lawsuit may help with a wide extent of Taxotere-related losses such as:

• Mental anguish
• Emotional distress
• Diminished quality of life
• Permanent disfigurement
• Loss of earnings and lost earning potential

The Chemotherapy Hair Loss Lawsuit is Case No. 2:18-cv-06423-JTM-MBN, in the U.S. District Court for the Eastern District of Louisiana. The Taxotere MDL is in re: Taxotere (Docetaxel) Products Liability Litigation, MDL No. 2740, in the U.S. District Court for the Eastern District of Louisiana.